$CANF

$1.72▲ +6.2% YTD

6 SEC 13D/G filings tracked · Last updated Nov 2, 2026

Filing History

CP $1.72▲ +6.2%Nov 2, 2026 · ThinkSabio Blog

$CANF - Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome…

News

CANF ▲ +10.1% - Can-Fite BioPharma Ltd.

CP $1.96▲ +10.1%Oct 26, 2026 · ThinkSabio Blog

$CANF - Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026…

News

CANF ▲ +1.8% - Can-Fite BioPharma Ltd.

CP $2.30▲ +1.8%Sep 9, 2026 · ThinkSabio Blog

$CANF - Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation…

News

CANF ▲ +3.1% - Can-Fite BioPharma Ltd.

CP $2.30▲ +3.1%Sep 8, 2026 · ThinkSabio Blog

$CANF - Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivo…

News

CANF ▼ -13.1% - Can-Fite BioPharma Ltd.

CP $2.78▲ -13.1%Sep 2, 2026 · ThinkSabio Blog

$CANF - Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds…

News

CANF ▲ +39.4% - Can-Fite BioPharma Ltd.

CP $4.46▲ +39.4%Sep 2, 2026 · ThinkSabio Blog

$CANF - Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study…